• Plerixafor: Reframing CXCR4 in Tumor Trafficking

  2026-09-09

  Plerixafor (AMD3100) is more than a stem cell mobilization reagent: it is a strategic probe for CXCL12/CXCR4-dependent trafficking across tumor, hematopoietic, and inflammatory systems. This article connects platelet extravasation biology with translational experimental design, competitive positioning, and practical workflows.

• Zoledronic Acid: From Mechanism to Assay Design

  2026-09-08

  Zoledronic Acid is a nitrogen-containing bisphosphonate used in cancer and bone-disease research. This guide develops a decision-oriented assay framework, using a mechanistic psoriasis study to show how orthogonal validation can improve interpretation without conflating distinct biological systems.

• Carbohydrate-Decorated Nanoparticles for Macrophage Therapy

  2026-09-08

  Chen and colleagues developed biodegradable nanoparticles that combine a cationic lipid-like component with carbohydrate-decorated PLGA or PLGA-PEG to improve gene delivery to macrophages. Their comparison of mannose, galactose, dextran, and mixed carbohydrate surfaces shows that nanoparticle composition influences uptake, reporter expression, and the practical performance of macrophage-targeted gene delivery.

• Dabigatran Assays for Thrombin and CVD Research

  2026-09-07

  Dabigatran enables controlled, reversible thrombin inhibition across thrombin-generation, TT, aPTT, and PT workflows. This guide connects practical assay design with cardio-cerebrovascular research while addressing formulation, metabolite, and pathway-specific troubleshooting.

• Matrine, YTHDF1, and Thymoma Stemness

  2026-09-07

  A 2026 study reports that Matrine reduces stemness-associated behavior and promotes apoptosis in EL-4-B5 thymoma cells, with YTHDF1 and Wnt/β-catenin signaling emerging as candidate mediators. The findings establish a useful in vitro framework for studying thymoma stemness, but the absence of direct m6A measurements, animal experiments, and clinical validation limits mechanistic and translational conclusions.

• Jasplakinolide: Designing Better Actin Assays

  2026-09-05

  Jasplakinolide is a potent actin polymerization inducer and F-actin stabilizer for mechanistic cell biology. This guide explains how to convert its direct cytoskeletal activity into better-controlled assays, using chemical-genetic reasoning from jasmonate research to improve interpretation without conflating distinct pathways.

• (-)-JQ1 in Heterogeneous BET Assays

  2026-09-04

  (-)-JQ1 is more than an inactive control: this JQ1 stereoisomer helps separate stereospecific BET biology from cell-line-specific stress responses. Learn how to apply it to HPV-associated cancer biology and BRD4 target gene modulation.

• Gamma-linolenic acid: Applied Research Workflows

  2026-09-04

  Use Gamma-linolenic acid (GLA) to interrogate LTB4-linked inflammation, cellular stress, and apoptosis with controlled, solvent-aware workflows. A practical comparison with arachidonic acid research helps distinguish established anti-inflammatory applications from emerging nutritional-immunology questions.

• KU-55933 and the Next Era of ATM Biology

  2026-09-03

  KU-55933 offers translational researchers a selective way to interrogate ATM signaling, linking DNA damage response research with Akt regulation, cell-cycle control, and cancer biology. This thought-leadership perspective places the compound alongside emerging telomere–mitochondrial findings while clearly separating established evidence from forward-looking hypotheses.

• POx Lipids as PEG Alternatives for mRNA LNPs

  2026-09-03

  Holick and colleagues investigate poly(2-ethyl-2-oxazoline)-based lipids as tunable substitutes for PEG-lipids in mRNA lipid nanoparticles. By combining polymer synthesis, particle characterization, immunoreaction and transfection assays, and super-resolution microscopy, the study identifies a PEtOx-LNP formulation that outperformed the tested commercial PEG-lipid comparator and clarifies why chain length matters.

• Antiarrhythmic Drugs at Cardiac KCa2 Channels

  2026-09-02

  This 2017 study used automated whole-cell patch clamp to test whether clinically used antiarrhythmic drugs inhibit human KCa2.2 and KCa2.3 channels, atrial-enriched targets proposed for atrial fibrillation therapy. Only dofetilide and propafenone showed measurable inhibition, and their relatively high IC50 values argue against a major contribution of KCa2 block at therapeutic free plasma concentrations.

• Boc-D-FMK: From Caspase Blockade to Translation

  2026-09-02

  Boc-D-FMK is best positioned as a causal research tool: a cell-permeable pan-caspase inhibitor that helps translational scientists distinguish caspase-dependent apoptosis from persistent inflammatory and fibrotic signaling.

• sEV CD147 Drives HCC Angiogenesis via PI3K/Akt

  2026-09-01

  Huang et al. identified CD147-positive small extracellular vesicles as a circulating candidate marker of hepatocellular carcinoma and showed that they stimulate endothelial angiogenesis. The study links vesicle-associated CD147 to VEGFA induction through PI3K/Akt signaling, providing a mechanistic framework for liquid biopsy development and tumor–endothelium communication studies.

• Geneticin and the Next Logic of Translational Selection

  2026-09-01

  A mechanistic and strategic guide to using Geneticin and G418 Sulfate for robust cell selection, while interpreting translational findings across prostate cancer biology, engineered models, and antiviral research.

• FPR2/ALX in Autoimmune Astrocytopathy

  2026-08-31

  A 2026 study shows that activating FPR2/ALX with Quin-C1 limits AQP4-IgG- and complement-associated astrocytopathy in mice by reshaping microglial and natural killer cell responses. Its depletion and pathway-inhibition experiments identify microglia, NK cells, and SYK-AKT signaling as important components of the protective phenotype, while also highlighting limitations for translation to human NMOSD.

8100 records 1/540 page Next 12345 下5页 Last page